Efficacy Study of IMSA101 in Combination with Radiation and Immune Checkpoint Inhibitors in Patients with Oligoprogressive (OPD) and Oligometastatic (OMD) Solid Tumor Malignancies. IMSA101 is the first STING agonist to be advanced to randomized Phase 2 clinical studies.